Curis Inc (STU:CUS0)
€ 3.76 -0.06 (-1.57%) Market Cap: 31.77 Mil Enterprise Value: 15.10 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Curis Inc at Needham Healthcare Conference Transcript

Apr 14, 2020 / 04:00PM GMT
Release Date Price: €12.4 (+1.64%)
James Dentzer
Curis, Inc. - President & CEO

Good afternoon and welcome to the Needham Healthcare Conference for 2020. This is a virtual conference and I am Jim Dentzer, CEO of Curis. Curis' mission is to relentlessly develop innovative and differentiated therapeutics that improve the lives of cancer patients. And we do that by selecting the right targets, designing the right drugs and studying the right patients.

This leads us to a unique place in biotech where we are looking at novel first-in-class cancer drugs that we believe have significant potential in areas of unmet patient need. We are targeting blockbusters.

There are three drugs that meet that filter in our pipeline. The first one is CA-4948, the first-in-class inhibitor of IRAK4 in oncology. The second is CI-8993, a first in class antagonist, a monoclonal antibody targeting VISTA. And Fimepinostat, our first-in-class suppressor of MYC.

Over the last three years Curis has evolved steadily through the regulatory planning stage to clinical execution, and in 2020 we are expanding and reporting out data on 4948 in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot